Amyotrophic lateral sclerosis (ALS) has become an increasingly attractive area for the
pharmaceutical industry, the most experimentally tractable of the neurodegenerative …

It has been eight years since the Food and Drug Administration approved riluzole as the
only drug of established value in slowing disease progression for patients with ALS. The …

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder caused by damage of
motoneurons leading to paralysis state and long term disability. Riluzole is currently the only …

There is currently no effective treatment for amyotrophic lateral sclerosis (ALS), a
devastating disorder of the human nervous system that, due to motoneurone degeneration …

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that is currently
untreatable. Many compounds have been tested in laboratory-based models and in patients …

Amyotrophic lateral sclerosis (ALS) is a deadly CNS neurodegenerative disease. The way
ALS is now managed, from diagnosis to prognosis, is still not ideal despite many studies …

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that
primarily affects motor neurons in the brain and spinal cord. In the recent past, there have …

Amyotrophic lateral sclerosis (ALS) is a progressively fatal neuromuscular disorder
classically characterized by loss of upper and lower motor neurons from the cortex to the …

Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressing neurodegenerative
disease leading almost irrevocably to paralysis and death within 5 years after the first …

Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease of the
human motor system. Aetiological mechanisms implicated in the development of ALS have …